Soluble CD14 is essential for lipopolysaccharide-dependent activation of human intestinal mast cells from macroscopically normal as well as Crohn's disease tissue

Immunology

Volumn 143, Issue 2, 2014, Pages 174-183

  Brenner, Sibylle A ^a   Zacheja, Steffi ^b   Schäffer, Michael ^b   Feilhauer, Katharina ^c   Bischoff, Stephan C ^a   Lorentz, Axel ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

^b MARIENHOSPITAL STUTTGART   (Germany)

^c KATHARINENHOSPITAL   (Germany)

Author keywords

Cytokine expression; Inflammatory bowel disease; Lipopolysaccharide; Mast cell; Soluble CD14

Indexed keywords

CD14 ANTIGEN; IL8 PROTEIN, HUMAN; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI 0111 B4; MESSENGER RNA; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ARTICLE; CELL CULTURE; CLASSIFICATION; CROHN DISEASE; CYTOKINE EXPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE; MAST CELL; METABOLISM; PATHOLOGY; SOLUBLE CD14; TIME;

CYTOKINE EXPRESSION; INFLAMMATORY BOWEL DISEASE; LIPOPOLYSACCHARIDE; MAST CELL; SOLUBLE CD14;

ANTIGENS, CD14; CELLS, CULTURED; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; INTESTINES; LIPOPOLYSACCHARIDES; MAST CELLS; RNA, MESSENGER; TIME FACTORS; TOLL-LIKE RECEPTOR 4;

EID: 84908221459     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12299     Document Type: Article

References (45)

1. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012; 18:693-704.
2. Bischoff SC. Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 2009; 31:185-205.
3. Bischoff SC, Kramer S. Human mast cells, bacteria, and intestinal immunity. Immunol Rev 2007; 217:329-37.
4. St John AL, Abraham SN. Innate immunity and its regulation by mast cells. J Immunol 2013; 190:4458-63.
5. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10:440-52.
6. Kumar V, Sharma A. Mast cells: emerging sentinel innate immune cells with diverse role in immunity. Mol Immunol 2010; 48:14-25.
7. Krämer S, Sellge G, Lorentz A, Krueger D, Schemann M, Feilhauer K, Gunzer F, Bischoff SC. Selective activation of human intestinal mast cells by Escherichia coli hemolysin. J Immunol 2008; 181:1438-45.
8. Theoharides TC, Alysandratos KD, Angelidou A et al. Mast cells and inflammation. Biochim Biophys Acta 2012; 1822:21-33.
9. di Nardo G, Cucchiara S. Pathogenesis of inflammatory bowel disease. In: Walker-Smith J, Lebenthal E, Branski D, eds. Pediatric and Inflammatory Bowel Disease: Perspective and Consequences. Pediatr Adolesc Med. Basel: Karger Publishers, 2009:1-18.
10. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12:S3-9.
11. Stasikowska-Kanicka O, Danilewicz M, Glowacka A, Wagrowska-Danilewicz M. Mast cells and eosinophils are involved in activation of ulcerative colitis. Adv Med Sci 2012; 57:230-6.
12. Farhadi A, Keshavarzian A, Fields JZ, Jakate S, Shaikh M, Banan A. Reduced immunostaining for c-kit receptors in mucosal mast cells in inflammatory bowel disease. J Gastroenterol Hepatol 2007; 22:2338-43.
13. Lorentz A, Schwengberg S, Mierke C, Manns MP, Bischoff SC. Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease. Eur J Immunol 1999; 29:1496-503.
14. Bischoff SC, Wedemeyer J, Herrmann A et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996; 28:1-13.
15. Araki Y, Kakegawa T, Stadil F. Mast cells and histamine release in Crohn's disease. Kurume Med J 1993; 40:93-9.
16. King T, Biddle W, Bhatia P, Moore J, Miner PB Jr. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig Dis Sci 1992; 37:490-5.
17. Nolte H, Spjeldnaes N, Kruse A, Windelborg B. Histamine release from gut mast cells from patients with inflammatory bowel diseases. Gut 1990; 31:791-4.
18. Sarin SK, Malhotra V, Sen Gupta S, Karol A, Gaur SK, Anand BS. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig Dis Sci 1987; 32:363-7.
19. Sanderson IR, Leung KB, Pearce FL, Walker-Smith JA. Lamina propria mast cells in biopsies from children with Crohn's disease. J Clin Pathol 1986; 39:279-83.
20. Dvorak AM, Monahan RA, Osage JE, Dickersin GR. Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 1980; 11:606-19.
21. Lloyd G, Green FH, Fox H, Mani V, Turnberg LA. Mast cells and immunoglobulin E in inflammatory bowel disease. Gut 1975; 16:861-5.
22. Sellge G, Bischoff SC. Isolation, culture, and characterization of intestinal mast cells. Methods Mol Biol 2006; 315:123-38.
23. Hagenlocher Y, Bergheim I, Zacheja S, Schäffer M, Bischoff SC, Lorentz A. Cinnamon extract inhibits degranulation and de novo synthesis of inflammatory mediators in mast cells. Allergy 2013; 68:490-7.
24. Schwartz LB, Austen KF, Wasserman SI. Immunologic release of ß-hexosaminidase and ß-glucuronidase from purified rat serosal mast cells. J Immunol 1979; 123:1445-50.
25. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3.
26. Triantafilou M, Triantafilou K, Fernandez N. Rough and smooth forms of fluorescein-labelled bacterial endotoxin exhibit CD14/LBP dependent and independent binding that is influenced by endotoxin concentration. Eur J Biochem 2000; 267:2218-26.
27. Haziot A, Rong GW, Silver J, Goyert SM. Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. J Immunol 1993; 151:1500-7.
28. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42:145-51.
29. Talreja J, Dileepan K, Puri S, Kabir MH, Segal DM, Stechschulte DJ, Dileepan KN. Human conjunctival epithelial cells lack lipopolysaccharide responsiveness due to deficient expression of MD2 but respond after interferon-γ priming or soluble MD2 supplementation. Inflammation 2005; 29:170-81.
30. Kennedy MN, Mullen GE, Leifer CA, Lee C, Mazzoni A, Dileepan KN, Segal DM. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for toll-like receptor 4. J Biol Chem 2004; 279:34698-704.
31. Bandzar S, Gupta S, Platt MO. Crohn's disease: a review of treatment options and current research. Cell Immunol 2013; 286:45-52.
32. Abreu MT, Arnold ET, Thomas LS, Gonsky R, Zhou Y, Hu B, Arditi M. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002; 277:20431-7.
33. Suzuki M, Hisamatsu T, Podolsky DK. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular toll-like receptor 4-MD-2 complex. Infect Immun 2003; 71:3503-11.
34. Varadaradjalou S, Féger F, Thieblemont N, Hamouda N, Pleau J, Dy M, Arock M. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003; 33:899-906.
35. Tancowny BP, Karpov V, Schleimer RP, Kulka M. Substance P primes lipoteichoic acid- and Pam3CysSerLys4-mediated activation of human mast cells by up-regulating toll-like receptor 2. Immunology 2010; 131:220-30.
36. Kubo Y, Fukuishi N, Yoshioka M et al. Bacterial components regulate the expression of toll-like receptor 4 on human mast cells. Inflamm Res 2007; 56:70-5.
37. Okumura S, Kashiwakura J, Tomita H, Matsumoto K, Nakajima T, Saito H, Okayama Y. Identification of specific gene expression profiles in human mast cells mediated by toll-like receptor 4 and FcεRI. Blood 2003; 102:2547-54.
38. McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activation of murine mast cells. J Leukoc Biol 2001; 70:977-84.
39. Striz I, Mio T, Adachi Y, Bazil V, Rennard S. The CD14 molecule participates in regulation of IL-8 and IL-6 release by bronchial epithelial cells. Immunol Lett 1998; 62:177-81.
40. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158:2919-25.
41. Funda DP, Tuckova L, Farre MA, Iwase T, Moro I, Tlaskalova-Hogenova H. CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun 2001; 69:3772-81.
42. Smith PD, Smythies LE, Mosteller-Barnum M et al. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J Immunol 2001; 167:2651-6.
43. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007; 116:207-35.
44. He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10:309-18.
45. Kobayashi R, Okamura S, Ohno T, Saito H, Mori M, Ra C, Okayama Y. Hyperexpression of FcγRI and toll-like receptor 4 in the intestinal mast cells of Crohn's disease patients. Clin Immunol 2007; 125:149-58.